Literature DB >> 22178098

Toward rubella elimination in Europe: an epidemiological assessment.

Mark Muscat1, Laura Zimmerman, Sabrina Bacci, Henrik Bang, Steffen Glismann, Kåre Mølbak, Susan Reef.   

Abstract

BACKGROUND: The elimination of rubella and prevention of congenital rubella syndrome (CRS) by 2015 are established goals for Europe. Our aim was to review the epidemiology of rubella in relation to this goal.
MATERIAL AND METHODS: National surveillance institutions from 32 European countries provided information on rubella and CRS surveillance systems and data for 2000-08. We reported the number of notified rubella cases by year for countries with a national mandatory notification system for rubella covering total country population consistently throughout 2000-08 and analysed rubella surveillance data for 2008.
RESULTS: Throughout 2000-08, 24 countries conducted passive routine surveillance based on mandatory reporting rubella covering total country population. Altogether these countries reported 526,751 rubella cases. The median incidence per million inhabitants declined from 7.2 in 2000 to 0.3 in 2008. By 2008, the number of countries with mandatory notification systems for rubella increased to 28. These countries reported 21,475 rubella cases of which 1.5% (n=317) were laboratory-confirmed. Most cases (n=21,075; 98%) were reported from Poland, Italy and Romania. Ten countries reported zero rubella cases and five others reported an incidence of <1 per million inhabitants. In 2008, 20 CRS cases were reported from five countries.
CONCLUSION: The overall decline in rubella incidence and increase in the number of countries conducting rubella surveillance through a mandatory notification system are notable achievements toward the goal of rubella elimination in Europe. However, in a few countries with high rubella incidence the risk for CRS still exists. Achievement and maintenance of the required high vaccination coverage and high-quality surveillance of rubella and CRS including laboratory testing of all suspected cases are fundamental to eliminate rubella and prevent CRS in Europe. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22178098     DOI: 10.1016/j.vaccine.2011.12.016

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Results of the rubella elimination program in Catalonia (Spain), 2002-2011.

Authors:  Irene Barrabeig; Nuria Torner; Ana Martínez; Gloria Carmona; Pilar Ciruela; Joan Batalla; Josep Costa; Sergi Hernández; Luis Salleras; Angela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2013-01-08       Impact factor: 3.452

2.  Further efforts in the achievement of congenital rubella syndrome/rubella elimination.

Authors:  Vanessa Cozza; Domenico Martinelli; Maria Giovanna Cappelli; Silvio Tafuri; Francesca Fortunato; Rosa Prato
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 3.  Passive immunization for the public health control of communicable diseases: current status in four high-income countries and where to next.

Authors:  Megan K Young; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2013-06-19       Impact factor: 3.452

Review 4.  Post-exposure passive immunisation for preventing rubella and congenital rubella syndrome.

Authors:  Megan K Young; Allan W Cripps; Graeme R Nimmo; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2015-09-09

Review 5.  Using Seroprevalence and Immunisation Coverage Data to Estimate the Global Burden of Congenital Rubella Syndrome, 1996-2010: A Systematic Review.

Authors:  Emilia Vynnycky; Elisabeth J Adams; Felicity T Cutts; Susan E Reef; Ann Marie Navar; Emily Simons; Lay-Myint Yoshida; David W J Brown; Charlotte Jackson; Peter M Strebel; Alya J Dabbagh
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

6.  Effects of campaign for postpartum vaccination on seronegative rate against rubella among Japanese women.

Authors:  Takahiro Yamada; Junko Mochizuki; Masachi Hanaoka; Eriko Hashimoto; Akihide Ohkuchi; Mika Ito; Takahiko Kubo; Akihito Nakai; Shigeru Saito; Nobuya Unno; Shigeki Matsubara; Hisanori Minakami
Journal:  BMC Infect Dis       Date:  2014-03-21       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.